Géraud Dautzenberg

Chapter 6

REFERENCES Dasgupta, A. (2007) ‘Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management’, Clinica Chimica Acta , pp. 1–13. doi: 10.1016/j.cca.2006.08.026. Dealberto, M. J. C. C. (2007) ‘Valproate-induced hyperammonaemic encephalopathy: Review of 14 cases in the psychiatric setting’, International Clinical Psychopharmacology , pp. 330–337. doi: 10.1097/ YIC.0b013e3281c61b28. Dols, A. et al. (2016) ‘Do current national and international guidelines have specific recommendations for older adults with bipolar disorder? A brief report’, International Journal of Geriatric Psychiatry , pp. 1295–1300. doi: 10.1002/gps.4534. Evans, M. D., Shinar, R. and Yaari, R. (2011) ‘Reversible dementia and gait disturbance after prolonged use of valproic acid’, Seizure , 20(6), pp. 509–511. doi: 10.1016/j.seizure.2011.02.009. Greenblatt, D. J., Sellers, E. M. and Koch-Weser, J. (1982) ‘Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations’, The Journal of Clinical Pharmacology , 22(5– 6), pp. 259–263. doi: 10.1002/j.1552-4604.1982.tb02671.x. Jansen, A. J. G. et al. (2012) ‘Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia’, Netherlands Journal of Medicine , p. 329. Kodama, Y. et al. (2002) ‘Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy’, American Journal of Health-System Pharmacy , 59(9), pp. 835–840. doi: 10.1093/ajhp/59.9.835. De Maat, M. M. R., Van Leeuwen, H. J. and Edelbroek, P. M. (2011) ‘High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy’, Annals of Pharmacotherapy , 45(3). doi: 10.1345/aph.1P308. Naranjo, C. A. et al. (1981) ‘A method for estimating the probability of adverse drug reactions’, Clinical Pharmacology and Therapeutics , 30(2), pp. 239–245. doi: 10.1038/clpt.1981.154. Nasreddine, Z. S. et al. (2005) ‘The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment’, Journal of the American Geriatrics Society , 53(4), pp. 695–699. doi: 10.1111/j.1532-5415.2005.53221.x. Ng, F. et al. (2009) ‘The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments’, Bipolar Disorders , 11(6), pp. 559–595. doi: 10.1111/j.1399-5618.2009.00737.x. Reisberg, B. et al. (1982) ‘The global deterioration scale for assessment of primary degenerative dementia’, American Journal of Psychiatry , 139(9), pp. 1136–1139. doi: 10.1176/ajp.139.9.1136. Sajatovic, M., Madhusoodanan, S. and Coconcea, N. (2005) ‘Managing bipolar disorder in the elderly: Defining the role of the newer agents’, Drugs and Aging , pp. 39–54. doi: 10.2165/00002512 200522010-00003. Sriboonruang, T. et al. (2011) ‘The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: Analysis based on routine therapeutic drug monitoring data’, Journal of Clinical Psychopharmacology , 31(1), pp. 115–119. doi: 10.1097/ JCP.0b013e318203b405. Wallenburg, E. et al. (2017) ‘Monitoring protein-unbound valproic acid serumconcentrations in clinical practice’, Therapeutic Drug Monitoring , 39(3), pp. 269–272. doi: 10.1097/FTD.0000000000000405.

144